AC699
ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer
Phase 1Active
Key Facts
Indication
ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer
Phase
Phase 1
Status
Active
Company
About Accutar Biotechnology
Accutar Biotechnology is a private, AI-native drug discovery company that has advanced its lead candidate, AC699, into clinical development for breast cancer, earning FDA Fast Track designation. The company's platform integrates multiple proprietary AI modules for target analysis, virtual screening, and compound optimization to streamline the discovery process. With a seasoned leadership team and strategic collaborations, Accutar aims to reduce the time and cost of bringing new therapies to market, positioning itself at the intersection of computational biology and traditional pharmaceutical development.
View full company profile